↓ Skip to main content

A randomised trial of point-of-care tests for chlamydia and gonorrhoea infections in remote Aboriginal communities: Test, Treat ANd GO- the “TTANGO” trial protocol

Overview of attention for article published in BMC Infectious Diseases, October 2013
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
42 Dimensions

Readers on

mendeley
111 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A randomised trial of point-of-care tests for chlamydia and gonorrhoea infections in remote Aboriginal communities: Test, Treat ANd GO- the “TTANGO” trial protocol
Published in
BMC Infectious Diseases, October 2013
DOI 10.1186/1471-2334-13-485
Pubmed ID
Authors

Rebecca J Guy, Lisa Natoli, James Ward, Louise Causer, Belinda Hengel, David Whiley, Sepehr N Tabrizi, Basil Donovan, Christopher K Fairley, Steven B Badman, Annie Tangey, Handan Wand, Mark Shephard, David G Regan, David Wilson, David Anderson, John M Kaldor

Abstract

High prevalence rates of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) have been reported in Aboriginal people in remote and regional areas of Australia for well over two decades, and repeat positivity rates are high. To interrupt disease transmission and reduce the risk of complications, early diagnosis and treatment is important. However in many remote and regional areas there are long delays between testing for these curable sexually transmissible infections and providing treatment, due to both physical distance from laboratories and difficulties when recalling patients for subsequent management once results are available. Point-of-care (POC) tests have the potential to provide more timely diagnosis, to increase treatment and contact tracing, and in turn reduce CT and NG infection rates.Methods/designTTANGO (Test, Treat, ANd GO) is a cross-over cluster randomised controlled trial in 12 regional or remote Australian health services, which predominantly provide clinical services to Aboriginal people. The overall aim of TTANGO is to measure the clinical effectiveness, cost-effectiveness and cultural and operational acceptability of molecular POC testing for CT and NG infection. The primary outcome is repeat positivity at three months after treatment of an initial CT or NG infection.Participating health services will undertake the clinical management of CT and NG under two different modalities for one year each. In the first year, six health services will be randomly assigned to manage these infections under current diagnostic guidelines. The other six will supplement current diagnostic guidelines with POC testing, whereby diagnosis is made and subsequent treatment for those with positive POC tests is offered at the initial consultation. In the second year, the health services will cross over to the opposite management modality.TTANGO will be conducted over four years; 1.5 years of trial initiation and community consultation, 2 years of trial conditions and evaluation, and 6 months of data analysis and feedback.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 111 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Canada 1 <1%
Unknown 109 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 23 21%
Researcher 17 15%
Student > Ph. D. Student 11 10%
Student > Bachelor 11 10%
Student > Postgraduate 7 6%
Other 18 16%
Unknown 24 22%
Readers by discipline Count As %
Medicine and Dentistry 21 19%
Nursing and Health Professions 12 11%
Social Sciences 9 8%
Agricultural and Biological Sciences 8 7%
Biochemistry, Genetics and Molecular Biology 7 6%
Other 25 23%
Unknown 29 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 November 2013.
All research outputs
#18,351,676
of 22,727,570 outputs
Outputs from BMC Infectious Diseases
#5,577
of 7,660 outputs
Outputs of similar age
#157,984
of 211,746 outputs
Outputs of similar age from BMC Infectious Diseases
#97
of 132 outputs
Altmetric has tracked 22,727,570 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,660 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 15th percentile – i.e., 15% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 211,746 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 132 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.